I brought up this subject last Dec & wow what a discussion, negativity, name calling until some posts deleted ... emotions ran high is some folks. There was also some good input.
I was just trying to collect information & opened the proverbial "can of worms".
Here's the link to that discussion for those of you who have some time and want to read how emotional folks can get ...
http://www.medhelp.org/posts/Hepatitis-C/Hemopurifier-or-VRAD/show/1118968
For those of you that don't yet know , DFPP is very similar to Hemopurification .. Double Plasmapheresis Filtration , it has been researched with Trials in Japan and found to be helpful enough in HCV Tx that the Japanese Govt . supports it and helps to pay the bills for their citizens.
Nobody says it is a cure , only that the filtration approach helps in clearing and achieving SVR in conjunction with SOC Tx , anyone opposed to that .. must have a personal problem. Attitude problem's do not help anyone here , we are all in this together. Constructive criticism is ok , normal, however anything more than that is destructive and non productive.
For the non biased clinical information Flguy and others are asking for ... link to the following webpage. The information is available ... you just have to look ...
Links to : Scholarly review's: Use of Double Filtration Plasmapheresis in HCV treatment :
http://scholar.google.com/scholar?q=DFPP+hcv+treatment+japan&hl=en&as_sdt=0&as_vis=1&oi=scholart
Another review : from 2007
http://onlinelibrary.wiley.com/doi/10.1111/j.1872-034X.2007.00117.x/abstract
Aim: The efficacy and safety of double filtration plasmapheresis (DFPP) plus interferon (IFN) combination therapy were compared with those of IFN therapy alone in 193 chronic hepatitis C patients having a high hepatitis C virus ribonucleic acid load of difficult-to-treat genotype 1b.
Methods: All patients received either interferon alpha-2b (IFN-α-2b) monotherapy or combination therapies with ribavirin and IFN-α-2b or pegylated interferon alpha-2b (PEG-IFN-α-2b). Each patient individually decided whether to receive concomitant DFPP. DFPP was immediately followed by IFN treatment, and up to five sessions were given during the first week.
Results: Sixty patients decided to receive DFPP. In the DFPP plus PEG-IFN-α-2b therapy group (n = 30), viral load reduction at 4 weeks after the start of treatment was greater than innon-DFPP (n = 74) (2.47 vs 1.52, log, P = 0.010), and the sustained virus response was also higher (77.8% vs 50.0%), even in cases of re-treated patients (relapsers or non-responders to previous IFN therapies). Adverse events, mild and transient, were observed in 38.3% of all DFPP-treated patients.
Conclusion: DFPP plus IFN combination therapy produced a great reduction of viral load during the early stage of treatment and achieved a high sustained virus response, suggesting that this combination therapy may be a new modality for chronic hepatitis C patients at difficult-to-treat states.
I wish all the best success to the U.S. equivalent AEMD !